Single Use Bioreactor Market Size, Share, Strategic Outlook, 2026-2034

Market Overview

According to Fortune Business Insights, the global single use bioreactor market size was valued at USD 5.46 billion in 2025. The market is projected to grow from USD 6.41 billion in 2026 to USD 23.17 billion by 2034, exhibiting a CAGR of 17.43% during the forecast period. North America dominated the single use bioreactor market with a market share of approximately 35%.

Fortune Business Insights™ has deep-dived into these insights in its latest research report, titled “Single Use Bioreactor Market, 2026-2034.”

The analysis shows that the global market is growing rapidly owing to the increased use of biologics, significant cost savings, advancements in bioprocessing technology, and infrastructure development across emerging markets. For example, according to the U.S. Food and Drug Administration (FDA), 1,250 single-use bioreactor installations were completed in the U.S. biopharma sector in 2023. This trend indicates a strong demand for single-use bioprocessing systems worldwide.

Major Players Profiled in the Market Report:

• Eppendorf SE (Germany)
• Cytiva (U.S.)
• Sartorius AG (Germany)
• Thermo Fisher Scientific Inc. (U.S.)
• Cobetter (China)
• DH Life Sciences, LLC. (U.S.)
• Avantor, Inc. (U.S.)
• bbi-biotech (Germany)
• Distek, Inc. (U.S.)

Segments

Scalability and Seamless Process Integration to Propel Stirred-Tank Bioreactors Segment Growth
Based on product, the market is divided into systems (stirred-tank bioreactors, wave-mixed bioreactors, and others) and accessories (single-use media bags and others). The stirred-tank bioreactors segment leads the market owing to its ability to scale, fit seamlessly into existing biopharmaceutical processes, mix ingredients quickly, and integrate with monitoring software in large-scale cell culture operations. Meanwhile, wave-mixed bioreactors are gaining traction in vaccine manufacturing and regenerative medicine due to gentle mixing and low shear stress.

High Production of Monoclonal Antibodies and Complex Biologics to Drive Mammalian Segment Expansion
By cell type, the market is categorized into mammalian and microbial. The mammalian cell segment is leading the market as mammalian cells are the most preferred for producing monoclonal antibodies, vaccines, and complex therapeutic proteins, alongside their high compatibility with single-use systems. The microbial cell segment is also developing steadily for fast, cost-effective production of enzymes and insulin.

Pharmaceutical and Biotechnology Companies to Dominate the Market Due to High Biologics Demand
Based on end user, the market is segmented into pharmaceutical and biotechnology companies, CROs & CDMOs, and others. The pharmaceutical and biotechnology companies segment holds the largest market share owing to high biologics production, the rising adoption of disposable devices, and the need to reduce cross-contamination risks and lengthy cleaning validation requirements. Additionally, CROs and CDMOs are increasingly adopting these systems to support outsourced drug development and fast batch production.

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

For detailed market insights: https://www.fortunebusinessinsights.com/single-use-bioreactor-market-112696

Report Coverage
The report offers:

• Major growth drivers, restraining factors, opportunities, and potential challenges for the market.
• Comprehensive insights into regional developments.
• List of major industry players.
• Key strategies adopted by the market players.
• The latest industry developments include product launches, partnerships, mergers, and acquisitions.

Drivers & Restraints

Rising Biologics Demand, Cost Reductions, and CDMO Adoption to Propel Market Growth
The increasing global demand for biologics, biosimilars, monoclonal antibodies, vaccines, and advanced cell and gene therapies is a primary driver boosting the single use bioreactor market growth. Switching to single-use bioreactors (SUBs) cuts capital investment costs by approximately 42% compared to traditional stainless-steel reactors. Furthermore, Contract Development and Manufacturing Organizations (CDMOs) and CMOs are heavily adopting SUBs to flexibly handle multiple outsourced projects and accelerate batch-to-batch transitions.

However, concerns over extractables and leachables from plastic components, complex regulatory compliance, and volume limitations may hamper market growth. Biomanufacturers must conduct rigorous testing to meet strict, ever-changing safety standards regarding leachables, which can delay approvals and commercialization. Additionally, single-use bioreactors cannot operate beyond a capacity of nearly 6,000 liters, leaving large-scale biopharmaceutical plants reliant on traditional stainless-steel systems.

Regional Insights

High R&D Expenditure and Strong Biopharmaceutical Infrastructure Propels Market Growth in North America
North America holds a dominant single use bioreactor market share (accounting for approximately 35% of the biopharmaceutical industry) and is projected to experience robust growth during the forecast period. The region’s growth is attributed to a strong biopharma presence, massive R&D expenditures, advanced healthcare infrastructure, and supportive regulatory policies that foster innovation. Europe also holds a prominent position, ranked highly for biosimilar development driven by powerful academic and research centers and streamlined regulatory approval processes.

Asia Pacific is projected to be one of the fastest-growing regions in the market. The growth is attributed to rising investments in biomanufacturing, surging demand for biologics and biosimilars, and proactive government interventions aimed at promoting bioprocessing advancements and upgrading healthcare facilities across the region.

Single Use Bioreactor Market Future Growth:
The single use bioreactor market is experiencing robust growth, fueled by the integration of Bioprocessing 4.0, the rise of hybrid manufacturing facilities, and rapid expansion across emerging markets. Today's biomanufacturers are increasingly drawn to single-use systems optimized with artificial intelligence (AI) and machine learning, which enhance product yields, improve consistency, and minimize waste. Additionally, there is a growing shift toward hybrid plants that combine single-use and stainless-steel technologies, allowing manufacturers to flexibly scale operations up or down while keeping costs and capacity optimized. While North America and Europe continue to lead in R&D and biosimilar innovation, emerging regions such as Asia-Pacific, Latin America, and Africa are seeing a surge in demand driven by new bioproduction system installations.

Competitive Landscape

Growing Focus on Product Launches and Advanced Film Technologies to Propel Market Growth
The market features prominent players like Cytiva, Sartorius AG, Thermo Fisher Scientific Inc., Eppendorf SE, and others. These leading companies are accelerating growth through strategic initiatives such as launching scalable single-use reactor systems, developing puncture-resistant and leakproof container films, and engaging in mergers, acquisitions, and partnerships. Their proactive approach to delivering contamination-free, flexible biomanufacturing solutions continues to fuel the market’s momentum.

Key Industry Development

• March 2024: Getinge AB introduced the Single-Use Production Reactor (SUPR) system in 50-liter and 250-liter versions to offer greater flexibility and duality in downstream bioproduction.
• April 2023: Merck KGaA introduced the Ultimus single-use process container film, designed to withstand bioprocessing conditions with severe demands on puncture resistance and extreme leakproofness.

Uncover Japan’s Market Trends - Explore the Latest Single Use Bioreactor Market Insights